title: Pretreatment prediction of symptom response to proton pump inhibitor therapy.
abstract: OBJECTIVE
  This prospective pilot study investigated whether it is possible to predict the therapeutic response in both the early phase (1 week) and sustained phase (4 weeks) before starting proton pump inhibitor (PPI) therapy for functional dyspepsia (FD) or non-erosive reflux disease (NERD).
  
  
  METHODS
  We administered rabeprazole 10 mg for 4 weeks to NERD/FD patients, who also answered a modified version of the Frequency Scale for Symptoms of gastroesophageal reflux disease (GERD) (FSSG), which added a pain score to the FSSG. Total score (TS), reflux score (RS), dysmotility score (DS), and pain score (PS) were analyzed. Symptom improvement was defined as ≥ 50% improvement in each score.
  
  
  RESULTS
  We enrolled 83 patients (age [mean ± SD] 50.8 ± 15.8 years, 29 males, 54 females), of whom 62 could be classified into four groups: achieved symptom improvement within 1 week and maintained it for 4 weeks (Early-R, 40.3%); achieved symptom improvement within 1 week but lost it after 4 weeks (Temp-R, 9.7%); did not achieve symptom improvement within 1 week but did after 4 weeks (Late-R, 9.7%); and no improvement (Non-R, 40.3%). Mean TS, RS, DS, and PS in the Non-R group were significantly higher than in the Early-R group (23.9, 10.5, 11.0, and 2.4 vs 14.3, 6.8, 6.4, and 1.2). However, the Temp-R, Late-R, and Non-R groups could not be distinguished by TS, RS, or DS.
  
  
  CONCLUSIONS
  The magnitude of the pretreatment modified FSSG score seemed to be associated with the response at 1 week and 4 weeks.
authors.affiliation: Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Nagahara
authors.forename: Hiroto
authors.initials: H
authors.lastname: Miwa
authors.forename: Daisuke
authors.initials: D
authors.lastname: Asaoka
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shimada
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Kenshi
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Taro
authors.initials: T
authors.lastname: Osada
authors.forename: Mariko
authors.initials: M
authors.lastname: Hojo
authors.forename: Sumio
authors.initials: S
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005544:Forecasting; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D064750:Rabeprazole / Q000008:administration & dosage*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors; D064750:Rabeprazole
keywords: functional dyspepsia; non-erosive reflux disease; prediction; proton pump inhibitor